Drugs / PRG-2311
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06497361 | Jul 2024 → Jul 2027 expected | immunoglobulin G4-related sclerosing disease, lupus nephritis | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRG-2311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06497361 ↗ |
| Modality | Cell therapy | “PRG-2311 (CD19/BCMA-targeting CAR-T Cells)” NCT06497361 ↗ |
| Target | CD19 | “CD19/BCMA-targeting CAR-T Cells” NCT06497361 ↗ |